TG Therapeutics Inc. (NASDAQ: TGTX) saw its shares soar 5% in pre-market trading on Friday, following the company's announcement of an upcoming schedule of presentations highlighting data on its drug BRIUMVI® (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (RMS).
The data presentations, which will take place at the American Academy of Neurology (AAN) 2025 annual meeting from April 5-9 in San Diego, will showcase various aspects of BRIUMVI's efficacy and safety profile, as well as real-world observational data on the drug's use in MS patients.
Highlights of the presentations include long-term follow-up data from the ULTIMATE I and II Phase 3 trials, which evaluated BRIUMVI in patients with RMS over a 96-week period. Additionally, results from the ENHANCE Phase 3b study, assessing a modified BRIUMVI treatment regimen, will also be presented.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。